Litcius/Paper detail

Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from <i>Canarium Album (Lour.)</i> Raeusch

Fangzhao Chen, Luoping Yang, Ling-Yan Zhai, Yingna Huang, Feimin Chen, Wen‐Jun Duan, Jie Yang

2020Chemical Biology & Drug Design19 citationsDOI

Abstract

Abstract Methyl brevifolincarboxylate (MBC) was isolated from ethyl acetate extract of Canarium album (Lour.) Raeusch. The structure was identified, and the effect on influenza A virus infection was evaluated. MBC exhibited inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC 50 values of 27.16 ± 1.39 μM and 33.41 ± 2.34 μM. Mechanism studies indicated that MBC inhibited the replication of influenza A virus by targeting PB2 cap‐binding domain. Our results demonstrated MBC was a potent PB2 cap‐binding inhibitor and represented as a new type of promising lead compound for the development of anti‐influenza virus drugs from natural products.

Topics & Concepts

VirusVirologyChemistryBiologyTraditional medicineMicrobiologyMedicineInfluenza Virus Research StudiesImmune Response and InflammationNeuropeptides and Animal Physiology
Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from <i>Canarium Album (Lour.)</i> Raeusch | Litcius